0 references
Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by Reverse Phase Protein Array.
Thyroid2013pp. 130703231537001–130703231537001
Sophie Broutin, Frédéric Commo, Leanne de Koning, Bérengère Marty-Prouvost, Ludovic Lacroix, Monique Talbot, Bernard Caillou, Thierry Dubois, Anderson J. Ryan, Corinne Dupuy, Martin Schlumberger, Jean‐Michel Bidart
Abstract
Results confirmed the reliability and the utility of RPPA for screening global changes induced in signaling pathways by kinase inhibitors. MAPK and AKT were identified as the main pathways involved in vandetanib response in MTC models. Our results also suggest alternative routes for controlling the disease and provide a rationale for the development of therapeutic combinations based on the comprehensive identification of molecular events induced by inhibitors.
Related Papers
- → Activity of novel RET inhibitors against RET genotypes associated with medullary thyroid cancer.(2010)3 cited
- → Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer(2012)1 cited
- Experience with vandeta nib in medullary thyroid cancer(2014)
- → Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience)(2020)
- → SY33-2 New perspectives on the treatment of thyroid cancer: novel drugs for medullary thyroid cancer(2021)